CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Genzyme Corporation v. Ingenus Pharmaceuticals LLC

1:17-cv-00602

Overview

Case Number 1:17-cv-00602
Filing Date 2017-05-24
Status Terminated
Termination Date 2017-08-22
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 28:2201 Declaratory Judgment
Jury Demand None

Parties

Defendant

Ingenus Pharmaceuticals LLC Operating Company

Represented By

2 Attorneys Listed

Nikhil A. Heble

Email: nheble@blankrome.com

Adam V. Orlacchio

Blank Rome LLP

Tel: +1 (302) 425-6431
Fax: +1 (302) 397-2156

1201 N. Market Street, Suite 800

Plaintiff

Sanofi-Aventis U.S. LLC Operating Company

Represented By

2 Attorneys Listed

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Southern Research Institute NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Genzyme Corporation NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Karen R. Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500
Fax: +1 (302) 778-2600

1007 Orange Street, Suite 205, P.O. Box 1596

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5661136
2-halo-2'-fluoro ARA adenosines as antinoplastic agents
Filed: 1994-09-21
Issued: 1997-08-26
Expired (Term Ended) +1211d PTA
Expires: 2018-01-14

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1211 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(28 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT AND DECLARATORY JUDGMENT filed against Ingenus Pharmaceuticals LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2147466.) - filed by Southern Research Institute, Genzyme Corporation, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(ceg) (Entered: 05/24/2017)

Entry #1 • 2017-05-24
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (ceg) (Entered: 05/24/2017)

Entry #2 • 2017-05-24
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 4/14/2017. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 10/14/2019. (ceg) (Entered: 05/24/2017)

Entry #3 • 2017-05-24
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 5,661,136 A. (ceg) (Entered: 05/24/2017)

Entry #4 • 2017-05-24
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sanofi SA for Genzyme Corporation, Sanofi-Aventis U.S. LLC filed by Genzyme Corporation, Sanofi-Aventis U.S. LLC, Southern Research Institute. (Bove, Jeffrey) (Entered: 05/24/2017)

Entry #5 • 2017-05-24
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc